# A Study of AZD1222, a Vaccine for the Prevention of COVID-19 in Immunocompromised Adults

> **NCT05057897** · PHASE4 · TERMINATED · sponsor: **AstraZeneca** · enrollment: 34 (actual)

## Conditions studied

- COVID-19, SARS-CoV-2

## Interventions

- **BIOLOGICAL:** AZD1222

## Key facts

- **NCT ID:** NCT05057897
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-01-31
- **Primary completion:** 2023-04-19
- **Final completion:** 2023-04-19
- **Target enrollment:** 34 (ACTUAL)
- **Why stopped:** Removal of the commitment for Immune compromised study (D81111C00010) due to recruitment challenges.
- **Last updated:** 2025-01-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05057897

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05057897, "A Study of AZD1222, a Vaccine for the Prevention of COVID-19 in Immunocompromised Adults". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05057897. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*